BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial B Bockorny, V Semenisty, T Macarulla, E Borazanci, BM Wolpin, ... Nature Medicine 26 (6), 878-885, 2020 | 352 | 2020 |
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature B Bockorny, I Codreanu, CA Dasanu British journal of haematology 156 (1), 50-66, 2012 | 148 | 2012 |
Suppression of adaptive responses to targeted cancer therapy by transcriptional repression M Rusan, K Li, Y Li, CL Christensen, BJ Abraham, N Kwiatkowski, ... Cancer discovery 8 (1), 59-73, 2018 | 103 | 2018 |
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature M Bockorny, S Chakravarty, P Schulman, B Bockorny, R Bona Acta haematologica 128 (4), 244-247, 2012 | 83 | 2012 |
PDX-derived organoids model in vivo drug response and secrete biomarkers L Huang, B Bockorny, I Paul, D Akshinthala, PO Frappart, O Gandarilla, ... JCI insight 5 (21), 2020 | 76 | 2020 |
Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score BJ Webb, K Dascomb, E Stenehjem, HR Vikram, N Agrwal, K Sakata, ... Antimicrobial agents and chemotherapy 60 (5), 2652-2663, 2016 | 75 | 2016 |
Autoimmune manifestations in large granular lymphocyte leukemia B Bockorny, CA Dasanu Clinical Lymphoma Myeloma and Leukemia 12 (6), 400-405, 2012 | 56 | 2012 |
OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models M Fabre, C Ferrer, S Domínguez-Hormaetxe, B Bockorny, L Murias, ... Clinical Cancer Research 26 (13), 3420-3430, 2020 | 53 | 2020 |
RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade B Bockorny, M Rusan, W Chen, RG Liao, Y Li, F Piccioni, J Wang, L Tan, ... Molecular cancer therapeutics 17 (7), 1526-1539, 2018 | 53 | 2018 |
Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer JE Grossman, L Muthuswamy, L Huang, D Akshinthala, S Perea, ... Clinical Cancer Research 28 (4), 708-718, 2022 | 49 | 2022 |
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial B Bockorny, T Macarulla, V Semenisty, E Borazanci, J Feliu, ... Clinical Cancer Research 27 (18), 5020-5027, 2021 | 43 | 2021 |
LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer A Bullock, J Grossman, M Fakih, H Lenz, M Gordon, K Margolin, B Wilky, ... Annals of Oncology 33, S376, 2022 | 38 | 2022 |
Discovery of new targets to control metastasis in pancreatic cancer by single-cell transcriptomics analysis of circulating tumor cells S Dimitrov-Markov, J Perales-Patón, B Bockorny, A Dopazo, M Muñoz, ... Molecular Cancer Therapeutics 19 (8), 1751-1760, 2020 | 34 | 2020 |
Facts and hopes in immunotherapy of pancreatic cancer B Bockorny, JE Grossman, M Hidalgo Clinical Cancer Research 28 (21), 4606-4617, 2022 | 33 | 2022 |
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial JI Zwicker, J Roopkumar, M Puligandla, BL Schlechter, AV Sharda, ... Blood Advances 4 (10), 2254-2260, 2020 | 24 | 2020 |
The emerging role of immunotherapy in gastric and esophageal adenocarcinoma B Bockorny, E Pectasides Future Oncology 12 (15), 1833-1846, 2016 | 24 | 2016 |
Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches B Bockorny, CA Dasanu Expert Opinion on Biological Therapy 13 (6), 911-925, 2013 | 22 | 2013 |
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated … AB El-Khoueiry, M Fakih, MS Gordon, AM Tsimberidou, AJ Bullock, ... Journal of Clinical Oncology 41 (4_suppl), LBA8-LBA8, 2023 | 19 | 2023 |
Association between HBsAg positivity and pancreatic cancer: a meta-analysis S Majumder, B Bockorny, WL Baker, CA Dasanu Journal of gastrointestinal cancer 45, 347-352, 2014 | 19 | 2014 |
HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence? B Bockorny, CA Dasanu Annals of hematology 94, 1-12, 2015 | 18 | 2015 |